DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "The Development of Therapeutic Monoclonal Antibody Products" report to their offering.
"The Development of Therapeutic Monoclonal Antibodies" Second Edition goes beyond other reports by incorporating the latest technical developments and integrating strategic and regulatory considerations with these technical requirements. This report will serve as a guide to product development companies, service providers, investors, and analysts as they work their way through the complex and rapidly evolving world of therapeutic monoclonal antibodies.
As the pharmaceutical market in the United States and the rest of the world continues to expand, biopharmaceutical products have taken on increasing importance in the treatment of disease. Sales of monoclonal antibody products have grown from approximately $50 billion in 2010 to almost $90 billion in 2015, an approximately 1.8-fold increase and represent approximately 58% of biopharmaceutical sales.
As more and more exciting monoclonal antibody products for treatment of cancer, autoimmune diseases, cardiovascular disease, and others are introduced, sales from new products approved in the coming years will drive the world-wide sales of monoclonal antibody products to approximately $110 billion by 2018 and nearly $150 billion by 2021.
Key Topics Covered:
Chapter 1: The Therapeutic Monoclonal Antibody Market
Chapter 2: Overview of Chemistry, Manufacturing, and Control Activities for Monoclonal Antibody Product Development
Chapter 3: Quality by Design
Chapter 4: Analytical Development
Chapter 5: Cell Line Development and Engineering
Chapter 6: Cell Culture Development and Scale-up
Chapter 7: Purification Development
Chapter 8: Formulation Development and Stability
Chapter 9: Drug Product Manufacturing
Chapter 10: Comparability
Chapter 11: Process Validation
Chapter 12: Manufacturing Strategies
For more information about this report visit https://www.researchandmarkets.com/research/gj5hxl/the_development